Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib

被引:93
作者
Prat, Aleix [1 ,2 ,3 ]
Cheang, Maggie C. U. [4 ]
Galvan, Patricia [2 ,3 ]
Nuciforo, Paolo [1 ]
Pare, Laia [2 ,3 ]
Adamo, Barbara [2 ,3 ]
Munoz, Montserrat [2 ,3 ]
Viladot, Margarida [2 ,3 ]
Press, Michael F. [5 ]
Gagnon, Robert [6 ]
Ellis, Catherine [7 ]
Johnston, Stephen [8 ]
机构
[1] Vall dHebron Inst Oncol, Translat Genom Grp, Passeig Vall dHebron 119-129, Barcelona 08036, Spain
[2] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[3] August Pi & Sunyer Biomed Res Inst, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
[4] Inst Canc Res, Div Clin Studies, Clin Trials & Stat Unit, London, England
[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Novartis Pharmaceut, Novartis, E Hanover, NJ USA
[7] GlaxoSmithKline Oncol, Collegeville, PA USA
[8] Royal Marsden Hosp, Dept Med Oncol, London, England
关键词
PROGESTERONE-RECEPTOR; GENE-EXPRESSION; POSTMENOPAUSAL WOMEN; ENDOCRINE THERAPY; MANAGEMENT; ER; PREDICTORS; RESISTANCE; SURVIVAL; EFFICACY;
D O I
10.1001/jamaoncol.2016.0922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE The value of the intrinsic subtypes of breast cancer (luminal A, luminal B, human epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in this study]-enriched, and basal-like) in the metastatic setting is currently unknown. OBJECTIVE To evaluate the association of the intrinsic subtypes of breast cancer with outcome and/or benefit in hormone receptor (HR)-positivemetastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS Unplanned retrospective analysis of 821 tumor samples (85.7% primary and 14.3% metastatic) from the EGF30008 phase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast cancer and no prior therapy for advanced or metastatic disease were randomized to letrozole with or without lapatinib, an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor. Tumor samples were classified into each subtype using the research-based PAM50 classifier. Prior neoadjuvant/adjuvant antiestrogen therapy was allowed. Patients with extensive symptomatic visceral disease were excluded. Treatment effects were evaluated using interaction tests. MAIN OUTCOMES AND MEASURES Primary and secondary end points were progression-free survival and overall survival. RESULTS The median (range) age was 62 (31-94) years. Intrinsic subtype was the strongest prognostic factor independently associated with progression-free survival and overall survival in all patients, and in patients with HER2-negative (n = 644) or HER2-positive (n = 157) diseases. Median progression-free survival differed across the intrinsic subtypes of clinically HER2-negative disease: luminal A (16.9 [95% CI, 14.1-19.9] months), luminal B (11.0 [95% CI, 9.6-13.6] months), HER2-enriched (4.7 [95% CI, 2.7-10.8] months), and basal-like (4.1 [95% CI, 2.5-13.8] months). Median OS also differed across the intrinsic subtypes: luminal A (45 [95% CI, 41-not applicable {NA}] months), luminal B (37 [95% CI, 31-42] months), HER2-enriched (16 [95% CI, 10-NA] months), and basal-like (23 [95% CI, 12-NA] months). Patients with HER2-negative/HER2-enriched disease benefited from lapatinib therapy (median PFS, 6.49 vs 2.60 months; progression-free survival hazard ratio, 0.238 [95% CI, 0.066-0.863]; interaction P =.02). CONCLUSIONS AND RELEVANCE This is the first study to reveal an association between intrinsic subtype and outcome in first-line HR-positivemetastatic breast cancer. Patients with HR-positive/HER2-negative disease with a HER2-enriched profile may benefit from lapatinib in combination with endocrine therapy. The clinical value of intrinsic subtyping in hormone receptor-positive metastatic breast cancer warrants further investigation, but patients with luminal A/HER2-negative metastatic breast cancer might be good candidates for letrozole monotherapy in the first-line setting regardless of visceral disease and number of metastases.
引用
收藏
页码:1287 / 1294
页数:8
相关论文
共 28 条
[1]   Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives [J].
Ades, Felipe ;
Zardavas, Dimitrios ;
Bozovic-Spasojevic, Ivana ;
Pugliano, Lina ;
Fumagalli, Debora ;
de Azambuja, Evandro ;
Viale, Giuseppe ;
Sotiriou, Christos ;
Piccart, Martine .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) :2794-+
[2]   ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J].
Cardoso, F. ;
Costa, A. ;
Norton, L. ;
Senkus, E. ;
Aapro, M. ;
Andre, F. ;
Barrios, C. H. ;
Bergh, J. ;
Biganzoli, L. ;
Blackwell, K. L. ;
Cardoso, M. J. ;
Cufer, T. ;
El Saghir, N. ;
Fallowfield, L. ;
Fenech, D. ;
Francis, P. ;
Gelmon, K. ;
Giordano, S. H. ;
Gligorov, J. ;
Goldhirsch, A. ;
Harbeck, N. ;
Houssami, N. ;
Hudis, C. ;
Kaufman, B. ;
Krop, I. ;
Kyriakides, S. ;
Lin, U. N. ;
Mayer, M. ;
Merjaver, S. D. ;
Nordstrom, E. B. ;
Pagani, O. ;
Partridge, A. ;
Penault-Llorca, F. ;
Piccart, M. J. ;
Rugo, H. ;
Sledge, G. ;
Thomssen, C. ;
van't Veer, L. ;
Vorobiof, D. ;
Vrieling, C. ;
West, N. ;
Xu, B. ;
Winer, E. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :1871-1888
[3]   Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Cardoso, F. ;
Harbeck, N. ;
Fallowfield, L. ;
Kyriakides, S. ;
Senkus, E. .
ANNALS OF ONCOLOGY, 2012, 23 :11-19
[4]   Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer [J].
Delpech, Y. ;
Wu, Y. ;
Hess, K. R. ;
Hsu, L. ;
Ayers, M. ;
Natowicz, R. ;
Coutant, C. ;
Rouzier, R. ;
Barranger, E. ;
Hortobagyi, G. N. ;
Mauro, D. ;
Pusztai, L. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (02) :619-627
[5]   Association between breast cancer subtypes and response to neoadjuvant anastrozole [J].
Dunbier, Anita K. ;
Anderson, Helen ;
Ghazoui, Zara ;
Salter, Janine ;
Parker, Joel S. ;
Perou, Charles M. ;
Smith, Ian E. ;
Dowsett, Mitch .
STEROIDS, 2011, 76 (08) :736-740
[6]   Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031 [J].
Ellis, Matthew J. ;
Suman, Vera J. ;
Hoog, Jeremy ;
Lin, Li ;
Snider, Jacqueline ;
Prat, Aleix ;
Parker, Joel S. ;
Luo, Jingqin ;
DeSchryver, Katherine ;
Allred, D. Craig ;
Esserman, Laura J. ;
Unzeitig, Gary W. ;
Margenthaler, Julie ;
Babiera, Gildy V. ;
Marcom, P. Kelly ;
Guenther, Joseph M. ;
Watson, Mark A. ;
Leitch, Marilyn ;
Hunt, Kelly ;
Olson, John A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2342-2349
[7]   Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [J].
Finn, Richard S. ;
Press, Michael F. ;
Dering, Judy ;
O'Rourke, Lisa ;
Florance, Allison ;
Ellis, Catherine ;
Martin, Anne-Marie ;
Johnston, Stephen .
CLINICAL CANCER RESEARCH, 2014, 20 (03) :736-743
[8]   Direct multiplexed measurement of gene expression with color-coded probe pairs [J].
Geiss, Gary K. ;
Bumgarner, Roger E. ;
Birditt, Brian ;
Dahl, Timothy ;
Dowidar, Naeem ;
Dunaway, Dwayne L. ;
Fell, H. Perry ;
Ferree, Sean ;
George, Renee D. ;
Grogan, Tammy ;
James, Jeffrey J. ;
Maysuria, Malini ;
Mitton, Jeffrey D. ;
Oliveri, Paola ;
Osborn, Jennifer L. ;
Peng, Tao ;
Ratcliffe, Amber L. ;
Webster, Philippa J. ;
Davidson, Eric H. ;
Hood, Leroy .
NATURE BIOTECHNOLOGY, 2008, 26 (03) :317-325
[9]   Challenges in the management of advanced, ER-positive, HER2-negative breast cancer [J].
Hart, Christopher D. ;
Migliaccio, Ilenia ;
Malorni, Luca ;
Guarducci, Cristina ;
Biganzoli, Laura ;
Di Leo, Angelo .
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (09) :541-552
[10]   Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer [J].
Johnston, Stephen ;
Pippen, John, Jr. ;
Pivot, Xavier ;
Lichinitser, Mikhail ;
Sadeghi, Saeed ;
Dieras, Veronique ;
Gomez, Henry Leonidas ;
Romieu, Gilles ;
Manikhas, Alexey ;
Kennedy, M. John ;
Press, Michael F. ;
Maltzman, Julie ;
Florance, Allison ;
O'Rourke, Lisa ;
Oliva, Cristina ;
Stein, Steven ;
Pegram, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5538-5546